177 related articles for article (PubMed ID: 9316881)
21. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system.
Griffin G; Wray EJ; Tao Q; McAllister SD; Rorrer WK; Aung MM; Martin BR; Abood ME
Eur J Pharmacol; 1999 Jul; 377(1):117-25. PubMed ID: 10448934
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.
Griffin G; Atkinson PJ; Showalter VM; Martin BR; Abood ME
J Pharmacol Exp Ther; 1998 May; 285(2):553-60. PubMed ID: 9580597
[TBL] [Abstract][Full Text] [Related]
23. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
[TBL] [Abstract][Full Text] [Related]
24. 5-Hydroxytryptamine1A and 5-hydroxytryptamine1B receptors stimulate [35S]guanosine-5'-O-(3-thio)triphosphate binding to rodent brain sections as visualized by in vitro autoradiography.
Waeber C; Moskowitz MA
Mol Pharmacol; 1997 Oct; 52(4):623-31. PubMed ID: 9380025
[TBL] [Abstract][Full Text] [Related]
25. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
[TBL] [Abstract][Full Text] [Related]
26. Agonist-stimulated [35S]GTPgammaS binding in brain modulation by endogenous adenosine.
Moore RJ; Xiao R; Sim-Selley LJ; Childers SR
Neuropharmacology; 2000 Jan; 39(2):282-9. PubMed ID: 10670423
[TBL] [Abstract][Full Text] [Related]
27. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
28. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoid receptor and WIN 55 212-2-stimulated [35S]-GTPgammaS binding in the brain of mu-, delta- and kappa-opioid receptor knockout mice.
Berrendero F; Mendizábal V; Murtra P; Kieffer BL; Maldonado R
Eur J Neurosci; 2003 Oct; 18(8):2197-202. PubMed ID: 14622180
[TBL] [Abstract][Full Text] [Related]
30. Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development.
Berrendero F; García-Gil L; Hernández ML; Romero J; Cebeira M; de Miguel R; Ramos JA; Fernández-Ruiz JJ
Development; 1998 Aug; 125(16):3179-88. PubMed ID: 9671590
[TBL] [Abstract][Full Text] [Related]
31. Azido- and isothiocyanato-substituted aryl pyrazoles bind covalently to the CB1 cannabinoid receptor and impair signal transduction.
Howlett AC; Wilken GH; Pigg JJ; Houston DB; Lan R; Liu Q; Makriyannis A
J Neurochem; 2000 May; 74(5):2174-81. PubMed ID: 10800963
[TBL] [Abstract][Full Text] [Related]
32. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats.
Drew LJ; Harris J; Millns PJ; Kendall DA; Chapman V
Eur J Neurosci; 2000 Jun; 12(6):2079-86. PubMed ID: 10886347
[TBL] [Abstract][Full Text] [Related]
33. Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A.
Petitet F; Marin L; Doble A
Neuroreport; 1996 Feb; 7(3):789-92. PubMed ID: 8733746
[TBL] [Abstract][Full Text] [Related]
34. AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain.
Hosohata Y; Quock RM; Hosohata K; Makriyannis A; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Feb; 321(1):R1-3. PubMed ID: 9083796
[TBL] [Abstract][Full Text] [Related]
35. Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5'O-(thio)-triphosphate binding in the basal ganglia of aged rats.
Romero J; Berrendero F; Garcia-Gil L; de la Cruz P; Ramos JA; Fernández-Ruiz JJ
Neuroscience; 1998 Jun; 84(4):1075-83. PubMed ID: 9578396
[TBL] [Abstract][Full Text] [Related]
36. Autoradiographic mapping of dopamine-D2/D3 receptor stimulated [35S]GTPgammaS binding in the human brain.
Sóvágó J; Makkai B; Gulyás B; Hall H
Eur J Neurosci; 2005 Jul; 22(1):65-71. PubMed ID: 16029196
[TBL] [Abstract][Full Text] [Related]
37. Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes.
Dennis I; Whalley BJ; Stephens GJ
Br J Pharmacol; 2008 Jul; 154(6):1349-58. PubMed ID: 18493244
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological properties of cannabinoid receptors in the avian brain: similarity of rat and chicken cannabinoid1 receptor recognition sites and expression of cannabinoid2 receptor-like immunoreactivity in the embryonic chick brain.
Fowler CJ; Nilsson O; Andersson M; Disney G; Jacobsson SO; Tiger G
Pharmacol Toxicol; 2001 Apr; 88(4):213-22. PubMed ID: 11322181
[TBL] [Abstract][Full Text] [Related]
39. The G protein-coupled cannabinoid-1 (CB1) receptor of mammalian brain: inhibition by phthalate esters in vitro.
Bisset KM; Dhopeshwarkar AS; Liao C; Nicholson RA
Neurochem Int; 2011 Oct; 59(5):706-13. PubMed ID: 21763743
[TBL] [Abstract][Full Text] [Related]
40. Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions.
Maher CE; Selley DE; Childers SR
Biochem Pharmacol; 2000 Jun; 59(11):1395-401. PubMed ID: 10751548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
